Burrill Starts Navidea Biopharmaceuticals (NAVB) at Market Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aegis Capital Starts Navidea Biopharmaceuticals (NAVB) at Hold
January 22, 2013 12:14 PM ESTEarlier, Aegis Capital initiates coverage on Navidea Biopharmaceuticals (NYSE: NAVB) with a Hold. PT $3.00.
NOTE: Burrill started at a Market Outperform today.
For an analyst ratings summary and ratings history on Navidea Biopharmaceuticals... More
